A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) [CardioVascular BioTherapeutics Inc] in Patients With Diabetic or Venous Stasis Ulcers
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2007
At a glance
- Drugs Fibroblast growth factor 1 (Primary)
- Indications Diabetic complications; Diabetic foot ulcer; Varicose ulcer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CardioVascular BioTherapeutics Inc
- 19 Nov 2007 Status changed from initiated to completed.
- 08 Nov 2007 New trial record.